Please assess the completion status of the following clinical trial:

Trial Title: T Cell Vaccination in Patients With Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically definite MS (according to Poser's criteria) of the relapsing-progressive type (RPMS).~2. Age: 18-60.~3. EDSS: 3.0 to 7.0.~4. Disease duration: \> 1 year.~5. Evidence of disease progression of 1 degree in the EDSS scale, or at least two severe relapses (requiring hospitalization and treatment) during the year prior to inclusion.~6. MRI of the brain with at least 5 lesions in the white matter (T2 imaging).~7. Failure to benefit from other existing treatments according to the guidelines of the Israeli Ministry of Health.~Exclusion Criteria:~1. Patients with other systemic active disease.~2. Patients who had been treated with immunosuppressive drugs during the 3-6 months depending on the cytotoxicity of the medication used prior to the inclusion.~3. Patients who previously received cellular immunotherapy or who are participating in other experimental protocols.~4. Pregnancy; Pregnant women or women who do not use efficacious contraception (oral contraception, or intra-uterine device).~5. Patients with an additional autoimmune condition unrelated to MS or significant allergy.~6. Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent, or in whom the clinician believes that a follow-up period of at least 12 months will not be possible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- TCV (Type: ACTIVE_COMPARATOR): multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
- Placebo (Type: SHAM_COMPARATOR): saline injections subcutaneously at the same 4 time points with active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).